EXACT Sciences (NASDAQ:EXAS) received a $95.00 target price from equities research analysts at Craig Hallum in a note issued to investors on Friday, February 22nd, The Fly reports. The firm presently has a “buy” rating on the medical research company’s stock. Craig Hallum’s price target indicates a potential upside of 5.00% from the stock’s current price.
Several other research firms have also weighed in on EXAS. UBS Group set a $100.00 target price on shares of EXACT Sciences and gave the stock a “buy” rating in a report on Tuesday, October 30th. Zacks Investment Research raised shares of EXACT Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, October 30th. Jefferies Financial Group increased their price objective on shares of EXACT Sciences from $74.00 to $84.00 and gave the stock a “buy” rating in a report on Wednesday, October 31st. BidaskClub raised shares of EXACT Sciences from a “sell” rating to a “hold” rating in a report on Friday, November 2nd. Finally, TheStreet raised shares of EXACT Sciences from a “d” rating to a “c-” rating in a report on Tuesday, November 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $99.64.
NASDAQ:EXAS traded down $0.67 during trading hours on Friday, hitting $90.48. 1,740,500 shares of the company traded hands, compared to its average volume of 1,863,737. The stock has a market cap of $11.46 billion, a P/E ratio of -66.53 and a beta of 1.85. EXACT Sciences has a twelve month low of $37.36 and a twelve month high of $97.27. The company has a debt-to-equity ratio of 1.02, a current ratio of 8.99 and a quick ratio of 8.70.
EXACT Sciences (NASDAQ:EXAS) last announced its quarterly earnings data on Thursday, February 21st. The medical research company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.05. EXACT Sciences had a negative net margin of 38.54% and a negative return on equity of 23.58%. The company had revenue of $142.98 million during the quarter, compared to analysts’ expectations of $143.00 million. During the same quarter in the prior year, the company posted ($0.18) EPS. The business’s revenue was up 63.6% on a year-over-year basis. As a group, equities research analysts anticipate that EXACT Sciences will post -1.98 EPS for the current year.
In related news, insider D Scott Coward sold 1,581 shares of the stock in a transaction that occurred on Thursday, January 3rd. The shares were sold at an average price of $62.75, for a total value of $99,207.75. Following the sale, the insider now directly owns 80,544 shares in the company, valued at approximately $5,054,136. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Kevin T. Conroy sold 304,397 shares of the stock in a transaction that occurred on Friday, January 25th. The shares were sold at an average price of $81.27, for a total transaction of $24,738,344.19. Following the completion of the sale, the insider now owns 1,190,408 shares in the company, valued at $96,744,458.16. The disclosure for this sale can be found here. Insiders sold a total of 445,896 shares of company stock worth $36,518,057 over the last quarter. 3.20% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of EXAS. Karp Capital Management Corp acquired a new stake in shares of EXACT Sciences in the fourth quarter valued at approximately $38,000. CWM LLC grew its stake in shares of EXACT Sciences by 777.1% in the fourth quarter. CWM LLC now owns 614 shares of the medical research company’s stock valued at $39,000 after buying an additional 544 shares in the last quarter. Hanson McClain Inc. grew its stake in shares of EXACT Sciences by 377.5% in the fourth quarter. Hanson McClain Inc. now owns 955 shares of the medical research company’s stock valued at $60,000 after buying an additional 755 shares in the last quarter. Tortoise Investment Management LLC bought a new position in shares of EXACT Sciences in the fourth quarter valued at $62,000. Finally, Phocas Financial Corp. bought a new position in shares of EXACT Sciences in the fourth quarter valued at $95,000. Institutional investors own 88.99% of the company’s stock.
EXACT Sciences Company Profile
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
Featured Story: What is a portfolio manager?
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.